Selling general and administrative expenses were $36 million for the second quarter, representing a $3.6 million increase over second quarter 2019, driven primarily by the initial gated infrastructure build of our EU operations, and offset by reduced travel and industry engagement in our commercial organization given restrictions in place to combat the COVID-19 pandemic.

Jul 30, 2020 / receipt, needs a key / Andrew, CFO | earnings call 2020-07-30 | transcript a6b00751-dae8-47b2-bb8c-f72008326982 | chars 17228-17601 | segment 17

As part of this exercise, we conducted a critical review of our spend across the business to capture reduced spending levels that will naturally occur due to the impact of the global pandemic, such as travel and clinical trial spend.

Apr 30, 2020 / receipt, needs a key / Andrew, CFO | earnings call 2020-04-30 | transcript 04b70d4a-8608-4912-b9e7-a743b799f651 | chars 20811-21044 | segment 20

There are some expenses that we would expect to, because of the delays, to potentially go down and just stay down, including some T&E and things like that.

Apr 30, 2020 / receipt, needs a key / Andrew Pendleton, CEO | earnings call 2020-04-30 | transcript 04b70d4a-8608-4912-b9e7-a743b799f651 | chars 26786-26941 | segment 26